CDC Website CDC Website

To Join the NPIN community or

Home » Long-acting Drug Delivery Systems for ART Optimization in HIV-1 Infected Children (R61/R33 Clinical Trial Not Allowed)

Long-acting Drug Delivery Systems for ART Optimization in HIV-1 Infected Children (R61/R33 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to accelerate development of safe and effective long-acting drug delivery systems (LA-DDS) for improved, simplified treatment of HIV-1 in children. This FOA invites applicants engaged in the development of existing LA-DDS platforms at early product development stages to perform specific preclinical activities that enable product optimization and accelerated translation to HIV-1 infected children. Collaborative research partnerships with industry are required.

Letter of Intent Date
2/13/19
Application Due Date
3/13/19
Project Start Date
12/1/19
Application Contact
Jenna
Briggs
Grants Management Specialist
301-761-5137
jenna.briggs@nih.gov
Technical Contact
Judi
Miller
Scientific Contact
jmillera@niaid.nih.gov
240-292-4801
Fund Duration
The total project period for an application submitted in response to this FOA is five years. Applicants may request up to two years of support for the R61 phase, and up to three years of support for the R33 phase.
Subjects
Audiences
Focus Area

Fund Number: 

5435

Fund ID: 

RFA-AI-18-057

Last Updated: 

11/20/18